{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lantus+%28glargine%29", "query": { "intervention": "Lantus (glargine)" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 306, "total_pages": 31, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lantus+%28glargine%29&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-24T20:41:04.093Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00115570", "title": "Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Insulin-Dependent" ], "interventions": [ { "name": "Insulin glulisine", "type": "DRUG" }, { "name": "insulin lispro", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" }, { "name": "NPH insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Years to 17 Years" }, "enrollment_count": 572, "start_date": "2005-04", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2016-05-20", "last_synced_at": "2026-09-24T20:41:04.093Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00115570" }, { "nct_id": "NCT03687827", "title": "A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin degludec", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 498, "start_date": "2018-10-02", "completion_date": "2019-12-27", "has_results": true, "last_update_posted_date": "2021-01-12", "last_synced_at": "2026-09-24T20:41:04.093Z", "location_count": 34, "location_summary": "Chandler, Arizona • Tucson, Arizona • Fresno, California + 28 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03687827" }, { "nct_id": "NCT06007508", "title": "Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "DKA" ], "interventions": [ { "name": "Insulin Glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "HealthPartners Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2022-05-31", "completion_date": "2023-02-28", "has_results": false, "last_update_posted_date": "2024-06-18", "last_synced_at": "2026-09-24T20:41:04.093Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06007508" }, { "nct_id": "NCT04864977", "title": "A Study of A Novel Approach to Titrate Basal Insulin (LY2963016) in Participants With Type 2 Diabetes", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes", "Type 2 Diabetes Treated With Insulin" ], "interventions": [ { "name": "Basal Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2021-08-16", "completion_date": "2022-06-06", "has_results": false, "last_update_posted_date": "2021-08-24", "last_synced_at": "2026-09-24T20:41:04.093Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04864977" }, { "nct_id": "NCT00279201", "title": "The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Lispro Low Mix", "type": "DRUG" }, { "name": "Lispro Mid Mix", "type": "DRUG" }, { "name": "Lispro", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "30 Years to 79 Years" }, "enrollment_count": 2091, "start_date": "2005-12", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2011-02-21", "last_synced_at": "2026-09-24T20:41:04.093Z", "location_count": 138, "location_summary": "Mobile, Alabama • Litchfield Park, Arizona • Little Rock, Arkansas + 135 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Litchfield Park", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00279201" }, { "nct_id": "NCT02420262", "title": "A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec/liraglutide", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 506, "start_date": "2015-07-26", "completion_date": "2016-10-05", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-09-24T20:41:04.093Z", "location_count": 50, "location_summary": "Tuscumbia, Alabama • Anaheim, California • Bermuda Dunes, California + 44 more", "locations": [ { "city": "Tuscumbia", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Bermuda Dunes", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Lancaster", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02420262" }, { "nct_id": "NCT00139659", "title": "A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma", "Diabetes Mellitus" ], "interventions": [ { "name": "Inhaled Insulin", "type": "DRUG" }, { "name": "Subcutaneous Insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "77 Years", "sex": "ALL", "summary": "18 Years to 77 Years" }, "enrollment_count": 288, "start_date": "2003-01", "completion_date": "2008-10", "has_results": true, "last_update_posted_date": "2010-06-02", "last_synced_at": "2026-09-24T20:41:04.093Z", "location_count": 86, "location_summary": "Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00139659" }, { "nct_id": "NCT02551874", "title": "A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Saxagliptin, Onglyza", "type": "DRUG" }, { "name": "Dapagliflozin, Farxiga", "type": "DRUG" }, { "name": "Glargine insulin", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 650, "start_date": "2015-10-20", "completion_date": "2017-11-10", "has_results": true, "last_update_posted_date": "2018-12-11", "last_synced_at": "2026-09-24T20:41:04.093Z", "location_count": 20, "location_summary": "Anaheim, California • Los Angeles, California • Miami, Florida + 15 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02551874" }, { "nct_id": "NCT00348374", "title": "Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Insulin Lispro", "type": "DRUG" }, { "name": "Exubera", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 191, "start_date": "2006-06", "completion_date": "2008-08", "has_results": true, "last_update_posted_date": "2010-03-16", "last_synced_at": "2026-09-24T20:41:04.093Z", "location_count": 62, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Malvern", "state": "Arkansas" }, { "city": "Foot Hill Ranch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00348374" }, { "nct_id": "NCT04039503", "title": "A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Tirzepatide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 475, "start_date": "2019-08-30", "completion_date": "2021-01-13", "has_results": true, "last_update_posted_date": "2022-01-12", "last_synced_at": "2026-09-24T20:41:04.093Z", "location_count": 5, "location_summary": "Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "Nashua", "state": "New Hampshire" }, { "city": "New York", "state": "New York" }, { "city": "Norman", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT04039503" } ] }